Suprasorb® CNPendo Used for Negative Pressure Therapy in the Oesophagus and Rectum to Support Defect and Wound Healing

RecruitingOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Esophagus InjuryRectal Lesion
Trial Locations (7)

48149

RECRUITING

Universitätsklinikum Münster (UKM) Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Münster

48431

RECRUITING

Klinikum Rheine, Mathias-Spital, Chirurgische Klinik I: Allgemein- und Viszeralchirurgie, Rheine

72076

RECRUITING

Universitätsklinikum Tübingen, Innere Medizin I - Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Tübingen

Unknown

RECRUITING

Uniklinik Berlin Charite, Berlin

RECRUITING

Central Interdisciplinary Endoscopy, II. Medical Clinic Mannheim Medical University, Mannheim

RECRUITING

Clinic for general, visceral and transplant surgery at the University of Munich, Munich

NOT_YET_RECRUITING

Uniklinik MRI, Munich

All Listed Sponsors
collaborator

CRI-The Clinical Research Institute GmbH

INDUSTRY

lead

Lohmann & Rauscher

INDUSTRY

NCT05476263 - Suprasorb® CNPendo Used for Negative Pressure Therapy in the Oesophagus and Rectum to Support Defect and Wound Healing | Biotech Hunter | Biotech Hunter